Loading stock…

Celldex Therapeutics, Inc. (CLDX) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Celldex Therapeutics, Inc.

CLDXMarket cap $2.43BPrice $31.0

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

Develops antibody-based therapies for cancer and rare inflammatory diseases, betting big on its lead drug barzolvolimab. With no approved products yet, its billion-dollar valuation rests entirely on late-stage trial data still to come.

In Bastion Portfolios?

52W Return+16%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)-13%1

Revenue Forecast

Rev CAGR (1y)-35%1

Rev CAGR (3y)+338%10

Rev CAGR (5y)+248%10

Earnings Forecast

EPS Growth Y+1Loss1

EPS Growth Y+2Loss1

EPS Growth Y+3Loss1

Quality

Margins

EBIT Margin-206220%1

Net Income Margin-190221%1

Free Cash Flow Margin-153231%1

Debt

Net Debt/EBITDAna–

Efficiency

ROE-44%1

ROA-41%1

Earnings Stabilityna–

GEAR+VERY WEAK4

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)na–

P/E Ratio (Forward 3y)na–

P/BV3.44

EV Multiples

EV/EBITDA Fwdna–

EV/EBIT Fwdna–

Yield

Free Cash Flow Yield-9.9%1

Dividend Yieldna–

Momentum

Short term

1 month return-22%1

3 month return-22%1

YTD return+14%7

Mid term

Price vs 52wHigh69%3

1 year return+18%7

Long term

3 year return+11%3

5 year return-44%2

Risk Shield

Price Risk

Beta1.42

Volatility51%3

Free Cash Flow

Free Cash Flow Margin-153231%1

Free Cash Flow Yield-9.9%1

Quality

ROCE-47%1

Earnings Stabilityna–

Net Debt/EBITDAna–

02Growth

Is it actually growing, and how fast?

CLDXCelldex Therapeutics

Revenue FY25$2M

GROWTH RATING↗

AVERAGE61 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-13%1

Revenue, next 1Y-35%1

Revenue, next 3Y, CAGR+338%10

Revenue, next 5Y, CAGR+248%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

Revenue is set to grow 338%/yr over the next 3 years, ahead of most of the market.7/10

After shrinking over the last 3 years, revenue is set to grow 338%/yr from here.

The runway holds up: revenue is set to grow 248%/yr over five years.10/10

WATCH

A mid-pack grower, ahead of 61% of companies worldwide.

WEAKNESSES

Revenue fell 13%/yr over the last 3 years, behind 90% of companies worldwide.1/10

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Reaccelerating Grower

A middle-of-the-pack grower that's turning around. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY WEAK11 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-22%1

3-month return-22%1

YTD return+14%7

MID & LONG-TERM▾SCORE

% of 52-week high69%3

1-year return+18%7

3-year return+11%3

5-year return-44%2

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming so far this year (+14%).

WATCH

It's up 18% over the past year, but 31% below its 52-week high. That is right in line with the market.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+11% over three years and -44% over five), behind 70% of the market.

The stock is underperforming over the past month (-22%) and over three months (-22%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Celldex Therapeutics, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

CLDXCelldex Therapeutics

Revenue FY25$2M

GROWTH RATING↗

AVERAGE61 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-13%1

Revenue, next 1Y-35%1

Revenue, next 3Y, CAGR+338%10

Revenue, next 5Y, CAGR+248%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

Revenue is set to grow 338%/yr over the next 3 years, ahead of most of the market.7/10

After shrinking over the last 3 years, revenue is set to grow 338%/yr from here.

The runway holds up: revenue is set to grow 248%/yr over five years.10/10

WATCH

A mid-pack grower, ahead of 61% of companies worldwide.

WEAKNESSES

Revenue fell 13%/yr over the last 3 years, behind 90% of companies worldwide.1/10

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Reaccelerating Grower

A middle-of-the-pack grower that's turning around. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY WEAK11 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-22%1

3-month return-22%1

YTD return+14%7

MID & LONG-TERM▾SCORE

% of 52-week high69%3

1-year return+18%7

3-year return+11%3

5-year return-44%2

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming so far this year (+14%).

WATCH

It's up 18% over the past year, but 31% below its 52-week high. That is right in line with the market.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+11% over three years and -44% over five), behind 70% of the market.

The stock is underperforming over the past month (-22%) and over three months (-22%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on Celldex Therapeutics, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community